跳至主要内容
临床试验/NCT05124405
NCT05124405进行中(未招募)不适用

Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices

M.D. Anderson Cancer Center2 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2018年5月24日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
35
试验地点
2
主要终点
To evaluate the feasibility of the ( PA) Physical Activity intervention.

研究概览

简要总结

To test the use of a continuous activity and heart rate tracker (Fitbit) and continuous glucose monitor (CGM) in monitoring daily exercise-related activities.

详细描述

Primary objective:

To evaluate the feasibility of a CGM-based physical activity intervention that includes the use of CGM and Fitbit®.

Secondary objectives:

To examine changes in physical activity motivation and other related psychosocial variables (e.g., intention, perceived benefits, outcome expectancy) before and after the intervention.

Exploratory objective:

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women at least 18 years old
  • Body mass index (BMI) 25 kg/m2
  • Engage in less than 150 minutes of moderate-intensity PA per week in the past month
  • Capable of participating in moderate-vigorous unsupervised exercise (as determined by the Physical Activity Readiness Questionnaire (PARQ) or a medical release from their physician)
  • Self-reported ability to walk one block without pain or discomfort
  • Have a smart phone with daily internet access that is compatible with the LibreLink app
  • Ability to speak, read, and write in English
  • For the cancer survivor cohort (participant accession number #21 and beyond), individuals must have been diagnosed with stage I-III breast or colorectal cancer and completed adjuvant therapy (i.e., chemo and/or radiation therapy).

排除标准

  • Self-reported current diagnosis or history of type 1 diabetes or type 2 diabetes
  • Self-reported use of oral antidiabetic agents (OADs)
  • Previous or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness including gestational is allowed at the discretion for the investigator)
  • Current use of a continuous glucose monitor
  • Fasting glucose > 125 mg/dL
  • Pregnancy
  • Self-reported health issues that limit physical activity
  • On dialysis
  • Work overnight shifts
  • Unwilling to use CGM
  • Current participation in other wellness or weight loss-related program or intervention
  • Currently on a low-carb diet
  • Unable to receive REDCap survey through their mobile phones

研究组 & 干预措施

Heart Rate Tracker (Fitbit)

Experimental

continuous heart rate activity

干预措施: Fitbit (Other)

Heart Rate Tracker (Fitbit)

Experimental

continuous heart rate activity

干预措施: Continuous Glucose Monitor (Other)

Continuous Glucose Monitor (CGM)

Experimental

monitoring daily exercise-related activities

干预措施: Fitbit (Other)

Continuous Glucose Monitor (CGM)

Experimental

monitoring daily exercise-related activities

干预措施: Continuous Glucose Monitor (Other)

结局指标

主要结局

To evaluate the feasibility of the ( PA) Physical Activity intervention.

时间窗: through study completion, an average of 1 year

The use of CGM through the following criteria: CGM-specific refusal rate \<20% at the participant recruitment phase and protocol adherence rates \>80% at the end of the monitoring period.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验